MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announced its
results for the three-months ended March 31, 2019, which are also
available on SEDAR (www.sedar.com).

The Company reported revenue of $184,801 for the three months ended
March 31, 2019, compared with revenue of $226,122 for the three months
ended March 31, 2018. Revenues from SIAscopy of $21,563 were lower than
the 2018 three-month period, and revenue from the Company’s therapeutic
laser line of $163,238 were 13% lower than in the prior year. The
Company reported a loss for the three months ended March 31, 2019 of
$788,101 or $0.01 per share compared with a loss of $672,154, or $0.01
per share for the three months ended March 31, 2018.

“The higher loss for the first quarter of 2019 resulted primarily from
additional investment in our new DermSecure telemedicine platform,”
noted Scott Spearn, CEO of MedX, “in addition to non-cash expenses
related to share option grants in 2018. We are still pivoting from
marketing SIAscopy from the sales of a single devices to marketing
SIAscopy as a telemedicine solutions and are confident that launching
DermSecure in Canada, the Netherlands, Spain and other major markets in
2019 will provide significant revenue growth as well as deliver the
benefits of shortening wait times, saving lives and lowering costs to
the health care system.”

MedX also announces that on May 23, 2019, it completed the closing of a
private placement, raising $136,000 by issuance of 850,000 Units. Each
Unit, sold at $0.16, is comprised of One (1) fully paid common share and
One (1) Share Purchase Warrant, exercisable to purchase One (1) further
Common Share at the price of $0.25, exercisable for a period of two
years from the date of issue. Following this Closing, MedX has
140,632,651 common shares issued and outstanding.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device
and software company focused on skin cancer with its DermSecure
telemedicine platform, utilizing its SIAscopy technology. SIAscopy is
also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which
MedX manufactures in its ISO 13485 certified facility. SIAMETRICS,
SIMSYS, and MoleMate include hand-held devices that use patented
technology utilizing light and its remittance to view up to 2 mm beneath
suspicious moles and lesions in a pain free, non-invasive manner, with
its software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use
in Canada, the US, Australia, New Zealand, the European Union and
Turkey. MedX also designs, manufactures and distributes quality
photobiomodulation therapeutic and dental lasers to provide drug-free
and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for
sale. This press release contains certain forward-looking statements
within the meaning of applicable Canadian securities legislation. These
forward-looking statements involve certain risks and uncertainties that
could cause actual results to differ, including, without limitation, the
company’s limited operating history and history of losses, the inability
to successfully obtain further funding, the inability to raise capital
on terms acceptable to the company, the inability to compete effectively
in the marketplace, the inability to complete the proposed acquisition
and such other risks that could cause the actual results to differ
materially from those contained in the company’s projections or
forward-looking statements. All forward looking statements in this press
release are based on information available to the company as of the date
hereof, and the company undertakes no obligation to update
forward-looking statements to reflect events or circumstances occurring
after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press release.

Contacts

Scott Spearn, President and CEO
MedX Health Corp
905-670-4428
ext 229

Media Relations
Deborah Thompson
[email protected]
416-918-9551